Kristin Abate

Kristin Abate is a declared insider of Karyopharm Therapeutics Inc. (senior executive), with filings sourced from SEC (Form 4). The record holds 15 filings, for trades running from 28 February 2025 to 16 October 2026.

The open-market record consists of 10 sales worth €14k, with no purchase. The rest of the record consists of 5 share grants. In 2026 alone, the filings show no purchases and 5 sales.

Most recently, on 19 October 2026, the filings show an open-market sale worth €1,469 in Karyopharm Therapeutics Inc. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.